CARCINOID CARDIAC SYNDROME: PRINCIPLES OF DIAGNOSIS AND TREATMENT


Cite item

Full Text

Abstract

Neuroendocrine tumors have the ability to produce hormones and vasoactive peptides, and their hyperproduction leads to various pathological changes in affected organs. In particular, endocardial fibroelastosis, ie, carcinoid cardiac syndrome (CCS) develops in heart. To date, cardiovascular complications in patients with CCS are one of the leading causes of death, therefore, timely diagnosis and treatment lead to significant improvements in quality of life of patients. This article is dedicated to the current state of cardiac lesions against the background of neuroendocrine tumors. A brief historical note about this problem is presented; the clinical symptoms, biochemical and instrumental methods of diagnosis are described in detail. General principles of treatment of CCS are represented.

References

  1. Muller JE, Connolly HM, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med 2003;348:1005-15.
  2. Shehata BM, Thomas JE, Doudenko-Rufforny I. Metastatic carcinoid to the conducting system-is it a rare or merely unrecognized manifestation of carcinoid cardiopathy? Arch Pathol Lab Med 2002;126:1538-40.
  3. Biork G, Axen O, Thorson A. Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency. Fatal outcome after angiocardiography. Am Heart J 1952;44:143-48.
  4. Irvin M, Oberg MK. A Century of Advances in Neuroendocrine Tumor. Biol Treat 2007:294.
  5. Mansencal N, Mitry E, Forissier JF, et al. Assessment of patient foramen ovale in carcinoid heart disease. Am Heart J 2006;1-6:1129.
  6. Ohri SK, Schofield JB, Hodgson H, et al. Carcinoid heart disease: early failure of an allograft valve replacement. Ann Thorac Surg 1994;58:1161-63.
  7. Ridker PM, Chertow GM, Karlson EW, et al. Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. Am Heart J 1991;121:1835-38.
  8. Горбунова В.А., Орел Н.Ф., Егоров Г.Н., Кузьминов А.Е. Высокодифференцированные нейроэндокринные опухоли (карциноиды) и нейроэндокринные опухоли поджелудочной железы. М., 2007. C. 103.
  9. Rajamannan NM, Caplice N, Anthikad F, et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 2001;10:827-31.
  10. Lundin L, Norheim I, Landelius J, et al. Carcinoid heart disease: relationship of circulating vasoactive substance to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264-69.
  11. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-96.
  12. Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, yransforming growth factor-beta and fibroblast growth factor. Cancer 2003;97:1609-15.
  13. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-88.
  14. Elangbam CS, Wehe JG, Barton JC, et al. Evaluation of glycosaminoglycanc content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitralvalvulopathy - a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats? Exp Toxicol Pathol 2006;58:89-99.
  15. Hoffmann J, Grimm W, Menz V, et al. Rate variability in carcinoid heart disease. Am J Cardiol 1999;83:128-31.
  16. Langer C, Piper C, Vogt J, et al. Atrial fibrillation in carcinoid heart disease: The role of Serotonin. A review of the literature. Clin Res Cardiol 2007;96:114-18.
  17. Lundin L, Landelius J, Andren B, et al. Transoesophageal echocardiography improves the diagnostic value of cardiac ultrasound in patients with carcinoid heart disease. Br Heart J 1990;64:190-94.
  18. Moyssakis IE, Rallidis LS, Guida GF, et al. Incidence and evolution of carcinoid syndrome in the heart. J Heart Valve Dis 1997;6:625-30.
  19. Ross EM, Roberts WC. The carcinoid sindrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 1985;79:339-54.
  20. Connolly HM, Pellikka PA. Carcinoid heart disease. Current Cardiology Reports 2006;8:96-101.
  21. Ferrans VJ, Roberts WC. The carcinoid endocardial plaque; an ultrastructural study. Hum Pathol 1976;7:387-409.
  22. Gustafsson BI, Tшmmerеs K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Curculation 2005;111:1517-22.
  23. Howard RJ, Drobac M, Rider WD, et al. Carcinoid heart disease: diagnosis by two-dimensional echocardiography. Circulation 1982;66:1059-65.
  24. Zuetenhorst JM, Korse CM, Bonfrer JM, et al. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 2004;90:2073-79.
  25. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89:151-60.
  26. Moler JE, Pellikka PA, Bgernheim AM, et al. Prognosis of carcinoid heart disease analysis of 200 cases over two decades. Prognosis of carcinoid heart disease analysis of 200 cases over two decades. Circulation 2005;112:3320-27.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies